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Abstract
Vascular remodelling occurs during all stages of atherosclerotic progression. Anti-atherosclerotic drugs may function by
restoring regulation of the processes involved in remodelling of the extracellular matrix. A key group of enzymes involved
 .in these processes are the matrix metalloproteinases MMPs . Oestrogens have been demonstrated to possess anti-athero-
sclerotic properties at low concentrations while being associated with lesion formation at high concentrations. We examined
 .the effect of 17b-oestradiol on MMP-2 expression in human coronary artery CAVSMC and umbilical artery vascular
 .smooth muscle cells UAVSMC . MMP-2 expression was measured by chemiluminescent immunoblotting and quantified
by laser densitometry. pro-MMP-2 was secreted by VSMCs and increasing levels of 17b-oestradiol, from physiological
through supraphysiological, were associated with significant dose-dependent increases in MMP-2 levels in culture media.
This effect was dependent on de novo protein synthesis and could be antagonised by the oestrogen receptor antagonist,
tamoxifen, and the specific receptor antagonist ICI 182,780. 17b-Oestradiol appears to be a specific stimulator of MMP-2
release from human vascular cells. The concentration dependence of this effect suggests a basis for the differential effects of
low and high oestrogen levels on vascular integrity. q 1998 Elsevier Science B.V.
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1. Introduction
Regulation of vascular remodelling is a potential
mechanism through which vascular health may be
determined. Dysfunctional regulation of these pro-
cesses are known to be involved in the pathogenesis
of a number of diseases. A key group of enzymes
involved in these processes are the matrix metallopro-
 .teinases MMPs . The MMPs have been implicated in
w xrheumatoid arthritis 1 , tumorigenesis, tissue inva-
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w x w xsion 2 and, recently, in cardiovascular disease 3 .
MMPs appear to be involved in atherogenic smooth
w xmuscle cell proliferation 4 , and there is evidence
that increased expression of these enzymes in an
activated form within plaques may contribute signifi-
w xcantly to plaque rupture and haemorrhage 5 . Most
recently, calcium channel blockers have been shown
to cause a two-fold increase in MMP-2 activity in
vascular smooth muscle preparations, and this has
been proposed as an anti-atherosclerotic effect of
w xthese agents 6 .
Oestrogen replacement in postmenopausal women
is associated with a reduction in both coronary heart
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disease morbidity and mortality of approximately
w x50% 7,8 . Coronary angiography has revealed that
users of postmenopausal oestrogen have a relative
risk of coronary artery disease of 0.37–0.44 com-
w xpared to non-users 9,10 . In contrast, premenopausal
women undergoing oral contraceptive therapy exhibit
adverse effects of oestrogens. Studies of vascular
pathology, primarily those of Irey in the early 1970s,
demonstrated lesions in the vasculature ranging from
the pulmonary, systemic and portal circulations, and
w xin veins and arteries 11 . The distinct vascular
changes that were observed included endothelial pro-
liferation and intimal thickening and these were asso-
ciated with, and preceded, thrombotic occlusion.
Moreover, they were seen in the vasculature of preg-
w xnant and postpartum women 12 . These vascular
alterations have not been studied in depth but contin-
uing reports of increased vascular disease incidence
in oral contraceptive users indicate that they may still
present in women taking currently used formulations
w x13 .
It is believed that a significant component of the
action of oestrogens is mediated through direct ef-
fects on the vascular wall and oestrogen receptors
have been demonstrated in vascular smooth muscle
w xcells 14 . We hypothesise that oestrogens, which are
w xalso believed to act as calcium channel blockers 15 ,
may regulate MMP expression in vascular tissues.
We therefore studied the effect of the naturally occur-
ring 17b-oestradiol on the principal MMP synthe-
sised by human vascular smooth muscle cells, MMP-2
w x16 .
2. Materials and methods
Unless otherwise stated all chemicals were sup-
 .plied by Sigma Dorset, UK . Cell culture plastics
were supplied by Marathon Laboratory Supplies
 .London, UK . ICI 182,780 was a kind gift from
Zeneca Pharmaceuticals. The sequence of the human
MMP-2 promoter was obtained from the National
 .Centre for Biotechnology Information NCBI ; gen-
bank accession No. HSU96098.
Normal human coronary artery vascular smooth
 .muscle cells CAVSMCs were supplied by Clonetics
 .TCS Biologicals, Bucks, UK and were isolated
from a 39-year old Caucasian female. Cultures up to
passage 6 were used. These cells were grown accord-
ing to a standard protocol supplied by Clonetics.
Human umbilical cords were donated from a local
hospital after approval by the local Ethics Committee.
Umbilical artery vascular smooth muscle cells
 .UAVSMCs were extracted from the arteries by first
removing the endothelium by scraping and then cut-
ting 1 mm2 segments and allowing attachment to the
surface of a 25 cm2 flask. All culture media and
components were phenol red-free. Cultures were
 .maintained in DMEM containing 10% vrv Foetal
 .Calf Serum FCS at 378C in a humidified atmo-
 .sphere containing 5% vrv CO . Cultures up to2
passage 8 were used. Cells were plated onto 24-well
plates and grown to 90% confluence.
 .Cultures CAVSMC or UAVSMC were rendered
quiescent by preincubation in phenol red-free DMEM
 .containing 0.1% vrv FCS for up to 96 h. Cultures
were incubated in the absence or presence of test
 .reagents for 72 h in DMEM plus 0.1% vrv FCS.
Although earlier time points were examined, a time
course indicated that 72 h was optimal data not
.shown . A water-soluble cyclodextrin encapsulated
17b-oestradiol preparation was used range: 0.15–
.  .1500 nmolrl . Tamoxifen 150 nmolrl , ICI 182,780
 .  .100 nmolrl and cycloheximide 10 mmolrl were
prepared by dissolution in ethanol. Vehicle ethanol
.and cyclodextrin were tested for control purposes.
The maximum final concentration of each vehicle
was representative of the maximum final concentra-
  .tion in experimental samples ethanol: 0.1% vrv ;
.cyclodextrin: 1 mgrml . Supernatants were harvested
and stored at y208C until assayed.
Supernatants were diluted 1:1 in SDS-PAGE sam-
ple buffer 20 mM Tris–HCl, pH 6.8, 2 mM EDTA,
 .  .  .6% wrv SDS, 20% wrv sucrose, 0.16% vrv
.b-mercaptoethanol, trace of bromophenol blue . Cell
lysates were prepared by solubilisation in SDS-PAGE
sample buffer. Chemiluminescent molecular weight
markers were used for estimation of MMP-2 molecu-
 .lar weight New England Biolabs, Herts, UK . Equal
volumes of sample were loaded onto 8% SDS-PAGE
gels. Following electrophoresis, protein was trans-
ferred onto PVDF membranes. MMP-2 was detected
by enhanced chemiluminescent immunoblotting cou-
 .pled to hyperfilm Amersham, Berks, UK using a
sheep antiserum raised against the human protein
 .The Binding Site, West Midlands, UK . MMP-2 was
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observed as a single electrophoretic species and peak
area was quantified by laser densitometry Molecular
.Dynamics, Berks, UK coupled to image analysis
 .software ImageQuant, Molecular Dynamics, UK .
Each immunoblot contained control lanes ap-
.propriate vehicle treated samples against which the
experimental samples were compared. Comparisons
were only made between control and experimental
samples from individual 24 well plates. Statistical
significance was calculated against the appropriate
vehicle controls by unpaired Student’s t-test n is the
.number of separate experiments performed and re-
sults are expressed as mean"SEM.
3. Results
Immunoblotting of human CAVSMC and
UAVSMC culture supernatants revealed a single
polypeptide species of 72 kDa corresponding to inac-
tive MMP-2 zymogen. MMP-2 was virtually unde-
tectable in cell lysates. None of the MMP-2 detected
in supernatants was attributable to serum in the me-
dia. b-Cyclodextrin carrier treatment alone did not
affect MMP-2 immunoreactivity in culture super-
Fig. 1. Effect of 17b-oestradiol on MMP-2 release by human
UAVSMCs. Cells were rendered quiescent by prior incubation in
 .DMEMr0.1% vrv FCS and were then incubated for 72 h in
the presence or absence of the indicated concentrations of 17b-
oestradiol. MMP-2 levels were determined by immunoblotting
 .see Section 2 . Results are expressed as % of vehicle control"
 . SEM ns6–9 . Significance is calculated against controls ) P
.-0.05, )) P -0.01 .
Fig. 2. Effect of 17b-oestradiol on MMP-2 release by human
CAVSMCs. Cells were rendered quiescent by prior incubation in
 .DMEMr0.1% vrv FCS and were then incubated for 72 h in
the presence or absence of the indicated concentrations of 17b-
oestradiol. MMP-2 levels were determined by immunoblotting
 .see Section 2 . Results are expressed as % of vehicle control"
 . SEM ns2–4 . Significance is calculated against controls ) P
.-0.05, )) P -0.01, ))) P -0.001 .
natants. Doses of 17b-oestradiol were tested repre-
senting low and high menstrual cycle 0.15, 1.5
.  .nmolrl , pregnancy 15 nmolrl and supraphysiolog-
 .ical 150 nmolrl concentrations. In UAVSMC, these
 . yielded 24%"37% NS, ns6 , 74%"39% P-
.  .0.05, ns9 , 213%"68% P-0.01, ns9 and
 .512%"312% P-0.05, ns6 increases in MMP-2
levels in culture media respectively after 72 h Fig.
.1 . The responses to 15 and 150 nmolrl 17b-
oestradiol were significantly higher than the response
 .to 1.5 nmolrl 17b-oestradiol P - 0.05 . In
CAVSMC, these doses yielded 95%"31% P-
.  .0.01, ns3 , 102%"28% P-0.01, ns3 , 100%
 . "19% P-0.001, ns2 , 83%"18% P-0.01,
.ns4 increases in MMP-2 levels in culture media
 .respectively after 72 h Fig. 2 . A further dose of 1.5
mmolrl 17b-oestradiol was tested which yielded an
increase in MMP-2 levels of 41%"29% P-0.05,
.ns2 . This latter dose generated a significantly lower
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 .P-0.05 increase in MMP-2 levels than all other
doses.
Tamoxifen was tested for its effects alone, and in
combination with 17b-oestradiol in UAVSMCs.
 .Ethanol vehicle elicited a significant 98%"36%
 .P-0.01, ns6 rise in MMP-2 levels. After adjust-
ment for the effect of ethanol, tamoxifen at doses of
1.5 and 150 nmolrl, yielded a 188%"119% P-
.  .0.05, ns6 and 32%"30% NS, ns6 increase in
MMP-2 expression, respectively. As tamoxifen at a
dose of 150 nmolrl did not demonstrate significant
biological activity with regard to MMP-2, this dose
was tested in combination with 17b-oestradiol 15
.nmolrl and 150 nmolrl for a possible antagonist
effect. Tamoxifen significantly antagonised 17b-
oestradiol 15 nmolrl: P-0.01; 150 nmolrl: P-
.  .0.05 induced MMP-2 expression Fig. 3 .
The effect of the specific oestrogen receptor antag-
onist, ICI 182,780 on the 17b-oestradiol mediated
increase in MMP-2 was tested in CAVSMCs. Ethanol
 .caused a significant 29%"6% Ps0.01, ns4
increase in MMP-2 release from CAVSMCs. In the
 .presence of 17b-oestradiol 15 nmolrl , ICI 182,780
reduced the effect of oestrogen by 71%"11% P-
.0.05, ns3 over 72 h.
Fig. 3. Effect of tamoxifen on 17b-oestradiol mediated increases
in MMP-2 levels. Human UAVSMCs were treated with the
indicated concentrations of tamoxifen and 17b-oestradiol and
supernatants harvested and analysed by immunoblotting see
.Section 2 . Results are expressed as a percentage in relation to
 .  .vehicle ethanol control"SEM ns4–6 . Significance is calcu-
lated against the effect of 17b-oestradiol alone ) P -0.05,
.)) P -0.01 .
To investigate whether this action of oestrogen
was dependent on de novo protein translation we
tested the effect of the protein synthesis inhibitor
cycloheximide on MMP-2 release from CAVSMCs.
Cycloheximide significantly inhibited release of
MMP-2 over a 48-h period by 85%"10% P-
.0.001, ns6 . Longer incubations were not possible
due to alterations in cellular morphology in response
to prolonged protein synthesis inhibition. In the pres-
 .ence of 17b-oestradiol 150 nmolrl cycloheximide
treatment still resulted in a significant decrease in
MMP-2 release into the media of 90%"6% P-
.0.001, ns6 .
4. Discussion
Effects of oestrogens on the vasculature encom-
pass two apparently contradictory observations. Oe-
strogen replacement in postmenopausal women is
associated with a reduction in incidence of CHD of
w xapproximately 50% 7,8 , but it has long been recog-
nised that high circulating levels of oestrogen are
associated with the formation of vascular lesions that
w xprecede thrombus formation 11 . These lesions have
been observed in premenopausal women undergoing
oral contraceptive therapy and in pregnant and post-
w xpartum women 12 . Although previous studies have
suggested oestrogen mediated modulation of MMPs
w xin nonvascular tissues 17 , this study demonstrates
for the first time modulation by oestrogen of MMP-2
expression in vascular tissue. The natural oestrogen,
17b-oestradiol, dose-dependently enhanced release of
pro-MMP-2 from normal human umbilical artery
smooth muscle and this effect could be blocked by
the oestrogen receptor antagonist tamoxifen. In coro-
nary artery smooth muscle cells 17b-oestradiol also
caused significant increases in the release of pro-
MMP-2. This also was dependent on the oestrogen
receptor as it could be significantly attenuated by ICI
182,780. However, the dose response differed be-
tween the two tissues with the foetal tissue demon-
strating up to 6-fold increases in MMP-2 release.
This may represent differences between adult and
foetal tissue with respect to receptor signalling. Alter-
natively, it may simply reflect differential expression
capabilities in distinct tissues. The secretion of MMP-
2 by these cells was dependent on de novo protein
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translation as was the effect of 17b-oestradiol. The
dose response, coupled to evidence of the mediation
of this effect through the oestrogen receptor and the
requirement for de novo protein translation, is strongly
suggestive that this action is due to the classical
oestrogen receptor pathway of gene transcription. The
w xpromoter sequence for the human MMP-2 gene 18
reveals three half-palindromic oestrogen response el-
 .ements ERE of the type TGACCT at residues 93–
98, 143–148 and 866–871. The only other known
transcriptional activation sites within the MMP-2 pro-
w xmoter are two Sp1 sites 19 . It has been demon-
strated that functional interactions between the oe-
strogen receptor and the transcription activator Sp1
can regulate oestrogen-dependent transcriptional ac-
w xtivity of the vitellogenin A1 io promoter 20 . It is
possible to speculate that EREs present in the MMP-2
promoter, alone or in synergy with Sp1, mediate the
effect observed in this study.
The extracellular matrix is known to be in a con-
stant state of turnover that requires a balance between
w x w xcollagen deposition 21 and degradation 22 . In this,
three processes can be distinguished: synthesis of
ECM components, degradation of collagen by MMPs
and control of MMP activity. Control of MMP activ-
ity involves the tissue inhibitors of metalloproteinases
 . w xTIMPs 23 but it has also recently been demon-
strated that reactive oxygen species can activate zy-
w xmogen species of MMPs 24 . Dysfunctional regula-
tion of any of these processes can shift the balance of
ECM turnover with potential pathological conse-
quences. For example, PDGF-BB is raised in athero-
sclerotic lesions and promotes excessive collagen
w xdeposition 25 .
Our demonstration that low physiological doses of
oestrogen are associated with significant increases in
the expression of pro-MMP-2 release from human
arterial smooth muscle may indicate an ability of
oestrogen to alter the balance of ECM regulation by
increasing the availability of MMP-2 zymogen. In
postmenopausal women in whom increased collagen
deposition might be expected, modest increases in
MMP-2 could be anti-atherosclerotic or promote re-
modelling of existing lesions. Two-fold increases in
MMP-2 activity have been shown to attenuate excess
collagen deposition and this has been proposed as a
mechanism for the anti-atherosclerotic properties of
w xcalcium channel blockers 6 . However, the dose
dependency of the effect, at least in umbilical artery,
may accord with the emergence of vascular lesions in
younger women subjected to supra-normal levels of
w xoestrogen as in oral contraceptive users 11 and
w xpregnancy 12 .
The observation of the effect of tamoxifen on this
system is also significant. While a high dose of
tamoxifen had no significant effect on MMP-2 ex-
pression, a low dose significantly increased MMP-2
expression to a similar degree to pregnancy levels of
oestrogen. Tamoxifen may therefore act as an oestro-
gen agonist at low doses and be able to modulate
vascular remodelling.
This study reveals for the first time that oestrogen
may be involved, through a receptor mediated pro-
cess, in the modulation of extracellular matrix
turnover. The role of MMPs in vascular health and
disease and their interaction with sex hormones re-
mains largely unexplored and further work in this
area is warranted to determine how changes observed
in MMP expression in vitro relate to vascular in-
tegrity in vivo.
Acknowledgements
We wish to thank the staff at the Birth Unit of the
Hospital of St. John and St. Elizabeth, St. John’s
Wood, London for kindly supplying umbilical cords
for this study. We are grateful to the Heart Disease
and Diabetes Research Trust and the Cecil Rosen
Foundation for their support.
References
w x1 Y. Yoshihara, K. Obata, N. Fujimoto, K. Yamashita, T.
Hayakawa, M. Shimmei, Increased levels of stromelysin-1
and tissue inhibitor of metalloproteinases-1 in sera from
patients with rheumatoid arthritis, Arthritis Rheum. 38
 .1995 69–75.
w x2 J.M. Ray, W.G. Stetler-Stevenson, The role of matrix metal-
loproteases and their inhibitors in tumour invasion, metasta-
 .sis and angiogenesis, Eur. Respir. J. 7 1994 2062–2072.
w x3 C.M. Dollery, J.R. McEwan, A.M. Henney, Matrix metallo-
 .proteinases and cardiovascular disease, Circ. Res. 77 1995
863–868.
w x4 W.D. McMillan, B.K. Patterson, R.R. Keen, W.H. Pearce,
In situ localization and quantification of seventy-two-kilo-
dalton type IV collagenase in aneurysmal, occlusive, and
 .normal aorta, J. Vasc. Surg. 22 1995 295–305.
( )C.S. Wingro˝e et al.rBiochimica et Biophysica Acta 1406 1998 169–174174
w x5 Z.S. Galis, G.K. Sukhova, M.W. Lark, P. Libby, Increased
expression of matrix metalloproteinases and matrix degrad-
ing activity in vulnerable regions of human atherosclerotic
 .plaques, J. Clin. Invest. 94 1994 2493–2503.
w x6 M. Roth, O. Eickelberg, E. Kohler, P. Erne, L.H. Block,¨
Ca2q channel blockers modulate metabolism of collagen
within the extracellular matrix, Proc. Natl. Acad. Sci. U.S.A.
 .93 1996 5478–5482.
w x7 M.J. Stampfer, G.A. Colditz, W.C. Willett, J.E. Manson, B.
Rosner, F.E. Speizer, C.H. Hennekens, Postmenopausal oe-
strogen therapy and cardiovascular disease. Ten-year follow-
up from the nurses health study, N. Engl. J. Med. 325
 .1991 756–762.
w x8 D. Grady, S.M. Rubin, D.B. Petitti, C.S. Fox, D. Black, B.
Ettinger, V.L. Ernster, S.R. Cummings, Hormone therapy to
prevent disease and prolong life in postmenopausal women,
 .Ann. Intern. Med. 117 1992 1016–1037.
w x9 H.W. Gruchow, A.J. Anderson, J.J. Barboriak, K.A.
Sobocinski, Postmenopausal use of oestrogen and occlusion
 .of coronary arteries, Am. Heart J. 115 1988 954–963.
w x10 J.M. Sullivan, R. Vander Zwaag, G.F. Lemp, J.P. Hughes,
V. Maddock, F.W. Kroetz, K.B. Ramanathan, D.M. Mirvis,
Postmenopausal oestrogen and coronary atherosclerosis,
 .Ann. Intern. Med. 108 1988 358–369.
w x11 N.S. Irey, W.C. Manion, H.B. Taylor, Vascular lesions in
 .women taking oral contraceptives, Arch. Pathol. 89 1970
1–8.
w x12 N.S. Irey, H.J. Norris, Intimal vascular lesions associated
 .with female reproductive steroids, Arch. Pathol. 96 1973
227–234.
w x13 World Health Organization Collaborative Study of Cardio-
vascular Disease and Steroid Hormone Contraception, Ve-
nous thromboembolic disease and combined oral contra-
ceptives: results of international multicentre case-control
 .study, Lancet 346 1995 1575–1582.
w x14 R.H. Karas, B.L. Patterson, M.E. Mendelsohn, Human vas-
cular smooth muscle cells contain functional oestrogen re-
 .ceptor, Circulation 89 1994 1943–1950.
w x15 F. Zhang, J.L. Ram, P.R. Standley, J.R. Sowers, 17b-
Oestradiol attenuates voltage-dependent Ca2q currents in
A7r5 vascular smooth muscle cell line, Am. J. Physiol. 266
 .1994 C975–C980.
w x16 A.C. Newby, K.M. Southgate, M. Davies, Extracellular
matrix degrading metalloproteinases in the pathogenesis of
 .arteriosclerosis, Basic Res. Cardiol. 89 1994 59–70, Suppl.
1.
w x17 F. Schatz, C. Papp, E. Toth-Pal, C.J. Lockwood, Ovarian
steroid-modulated stromelysin-1 expression in human en-
dometrial stromal and decidual cells, J. Clin. Endocrinol.
 .Metab. 78 1994 1467–1472.
w x18 J. Bian, Y. Sun, Transcriptional activation by p53 of the
human type IV collagenase gelatinase A or matrix metallo-
.  .proteinase 2 promoter, Mol. Cell. Biol. 17 1997 6330–
6338.
w x19 P. Huhtala, L.T. Chow, K. Tryggvason, Structure of the
 .human type IV collagenase gene, J. Biol. Chem. 265 1990
11077–11082.
w x20 S.R. Batistuzzo-de-Medeiros, G. Krey, A.K. Hihi, W. Wahli,
Functional interactions between the oestrogen receptor and
the transcription activator Sp1 regulate the oestrogen-depen-
dent transcriptional activity of the vitellogenin A1 io pro-
 .moter, J. Biol. Chem. 272 1997 18250–18260.
w x21 G.J. Laurent, Dynamic state of collagen: pathways of colla-
gen degradation in vivo and their possible role in regulation
 .of collagen mass, Am. J. Physiol. 252 1987 C1–C9.
w x22 C. Gardi, P. Calzoni, P. Marcolongo, E. Cavarra, L Vanni,
G. Lungarella, Collagen breakdown products and lung colla-
gen metabolism: an in vitro study on fibroblast cultures,
 .Thorax 49 1994 312–318.
w x23 J.F. Woesnner, Matrix metalloproteinases and their in-
 .hibitors in connective tissue remodelling, FASEB J. 5 1991
2145–2154.
w x24 S. Rajagopalan, X.P. Meng, S. Ramasamy, D.G. Harrison,
Z.S. Galis, Reactive oxygen species produced by macrophage
foam cells regulate the activity of vascular matrix metallo-
proteinases in vitro. Implications for atherosclerotic plaque
 .stability, J. Clin. Invest. 98 1996 2572–2579.
w x25 R. Ross, J. Masuda, E.W. Raines, A.M. Gown, S. Katsuda,
M. Sasahara, L.T. Malden, H. Masuko, H. Sato, Localiza-
tion of PDGF-B protein in macrophages in all phases of
 .atherogenesis, Science 248 1990 1009–1012.
